secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0001193125-21-244019
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic Q2 2021 net loss narrows to $14.5M; PKU and Enteric Hyperoxaluria trials on track for 2H readouts
--------------------------------------------------------------------------------

- Cash, equivalents, and investments of $115.5M as of June 30, 2021; runway into second half of 2023.
- Net loss of $14.5M ($0.28/shr) vs. $15.5M ($0.44/shr) in Q2 2020; revenue of $0.2M from Roche IBD collaboration.
- SYNB1618 Phase 2 PKU trial ongoing; Phase 1 of next-generation SYNB1934 initiated in July 2021.
- SYNB8802 Enteric Hyperoxaluria Part B enrolling; proof-of-concept data expected in 2H 2021.
- Combination arm of SYNB1891 (atezolizumab) Phase 1 in solid tumors; mature data expected by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000119312521244019/0001193125-21-244019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000119312521244019/d340812d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-244019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer